OTCPK:MRNT.F

Stock Analysis Report

Executive Summary

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally.

Snowflake

Fundamentals

Overvalued with concerning outlook.


Similar Companies

Share Price & News

How has Medicrea International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

MRNT.F

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

21.1%

MRNT.F

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: MRNT.F exceeded the US Medical Equipment industry which returned 10% over the past year.

Return vs Market: MRNT.F exceeded the US Market which returned 5.4% over the past year.


Shareholder returns

MRNT.FIndustryMarket
7 Day0%3.2%3.4%
30 Day-14.3%-1.8%-1.0%
90 Dayn/a-0.4%-0.4%
1 Year21.1%21.1%10.9%10.0%7.7%5.4%
3 Yearn/a69.9%64.8%46.2%36.8%
5 Yearn/a128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is Medicrea International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medicrea International undervalued compared to its fair value and its price relative to the market?

2.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MRNT.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MRNT.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MRNT.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MRNT.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MRNT.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRNT.F is good value based on its PB Ratio (2.7x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Medicrea International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNT.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRNT.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRNT.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRNT.F's revenue (18.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MRNT.F's revenue (18.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if MRNT.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Medicrea International performed over the past 5 years?

-45.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MRNT.F is unprofitable, and losses have increased over the past 5 years at a rate of -45.4% per year.

Accelerating Growth: Unable to compare MRNT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRNT.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: MRNT.F has a negative Return on Equity (-81.8%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MRNT.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MRNT.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Medicrea International's financial position?


Financial Position Analysis

Short Term Liabilities: MRNT.F's short term assets (€28.3M) exceeds its short term liabilities (€13.4M)

Long Term Liabilities: MRNT.F's short term assets (28.3M) do not cover its long term liabilities (33.3M)


Debt to Equity History and Analysis

Debt Level: MRNT.F's debt to equity ratio (235.7%) is considered high

Reducing Debt: MRNT.F's debt to equity ratio has increased from 26.4% to 235.7% over the past 5 years.


Balance Sheet

Inventory Level: MRNT.F has a high level of physical assets or inventory.

Debt Coverage by Assets: MRNT.F's debt is not covered by short term assets (assets are 0.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MRNT.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MRNT.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Medicrea International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MRNT.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MRNT.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MRNT.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNT.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRNT.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Medicrea International's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Denys Sournac 0

0yrs

Tenure

€7,000

Compensation

Mr. Denys Sournac serves as the Owner, President and Chief Executive Officer at Orsco Laboratoire Vétérinaire, SAS. He also serves as the Chairman of Orsco Laboratoire Vétérinaire, SAS. Mr. Sournac has bee ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Denys's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Denys's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

Experienced Management: MRNT.F's management team is considered experienced (2 years average tenure).


Board Age and Tenure

17.6yrs

Average Tenure

60yo

Average Age

Experienced Board: MRNT.F's board of directors are seasoned and experienced ( 17.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Fabrice Kilfiger

    Chief Financial Officer

    • Tenure: 0yrs
  • Rick Kienzle

    Chief Commercial & Business Development Officer and Director

    • Tenure: 3.2yrs
  • Denys Sournac

    Co-Founder

    • Tenure: 0yrs
    • Compensation: €7.00k
  • Jean Caffiero

    Co-Founder

    • Tenure: 17.6yrs
    • Compensation: €7.00k
  • David Ryan

    Chief Operating Officer

    • Tenure: 0.8yrs
  • Nadège Bourdois

    Vice President of Human Ressources & Legal

    • Tenure: 0yrs
  • Rick Washburn

    Executive Vice President of UNiD™ ASI

    • Tenure: 2yrs
  • Pierre-Laurent Ravis

    Chief Information Officer

    • Tenure: 0yrs
  • Thomas Mosnier

    Chief Scientific Officer

    • Tenure: 0yrs
  • Joe Walland

    Chief Executive Officer of Medicrea USA

    • Tenure: 2yrs

Board Members

  • M. Ory (60yo)

    Independent Director

    • Tenure: 12.3yrs
    • Compensation: €4.00k
  • Patrick Bertrand (65yo)

    Director

    • Tenure: 17.6yrs
    • Compensation: €4.00k
  • Rick Kienzle

    Chief Commercial & Business Development Officer and Director

    • Tenure: 3.2yrs
  • Denys Sournac

    Co-Founder

    • Tenure: 0yrs
    • Compensation: €7.00k
  • Marc Recton

    Independent Director

    • Tenure: 16.3yrs
    • Compensation: €4.00k
  • Christophe Bonnet

    Independent Director

    • Tenure: 17.6yrs
    • Compensation: €4.00k
  • Jean Moreno

    Director

    • Tenure: 17.6yrs
    • Compensation: €4.00k
  • Jean Caffiero

    Co-Founder

    • Tenure: 17.6yrs
    • Compensation: €7.00k
  • Pierre Olivier (53yo)

    Director

    • Tenure: 1.4yrs
  • Pierre Burel

    Director

    • Tenure: 17.6yrs

Company Information

Medicrea International SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicrea International SA
  • Ticker: MRNT.F
  • Exchange: OTCPK
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €40.536m
  • Listing Market Cap: €44.736m
  • Shares outstanding: 16.21m
  • Website: https://www.medicrea.com

Number of Employees


Location

  • Medicrea International SA
  • 5389, route de Strasbourg
  • Rillieux-la-Pape
  • Rhône-Alpes
  • 69140
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALMEDENXTPA (Euronext Paris)YesOrdinary SharesFREURJun 2006
MRNT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2006

Biography

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; Li ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:13
End of Day Share Price2019/10/04 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.